Hepatitis and Viral Infections
Hepatitis Overview
Liver inflammation, often caused by viral infections (hepatitis viruses A, B, C, D, E), but also by bacteria, autoimmune diseases, or toxins (e.g., alcohol, certain drugs). This inflammation can range from acute illness to chronic conditions, potentially leading to progressive liver damage such as fibrosis, cirrhosis (scarring), and hepatocellular carcinoma (liver cancer).
Hepatitis viruses are a diverse group with different modes of transmission and clinical courses. A common symptom across many forms of hepatitis is jaundice, a yellowing of the skin and eyes, caused by the buildup of bilirubin in the blood due to impaired liver function.
Hepatitis A and E typically cause acute, self-limiting infections.
Hepatitis B, C, and D can lead to chronic infections, significantly increasing the risk of long-term liver disease.
Transmission
Hepatitis A (HAV): Primarily transmitted via the fecal-oral route. This occurs through the ingestion of contaminated food or water, especially in areas with poor sanitation. Close personal contact with an infected individual can also facilitate transmission.
Hepatitis B (HBV): Transmitted through mucosal contact with infectious bodily fluids (blood, semen, vaginal secretions, saliva). Key transmission routes include:
Sharing needles or other injection drug use equipment.
Unprotected sexual contact with an infected person.
Perinatal (congenital) transmission from an infected mother to her baby during birth.
Accidental needle-stick injuries, tattooing, or body piercing with unsterilized equipment.
Hepatitis C (HCV): Primarily transmitted through blood-to-blood contact. Common routes include:
Sharing needles or other injection drug use equipment (most common mode).
Perinatal (congenital) transmission from an infected mother to her baby during birth, though less common than HBV.
Less commonly, through sexual contact or shared personal items (e.g., razors, toothbrushes) contaminated with blood.
Historically, through blood transfusions and organ transplants before widespread screening.
Hepatitis A Clinical Progression
The progression of Hepatitis A generally involves several stages in acute infection:
Exposure: Ingestion of HAV-contaminated food or water.
Incubation Period: Typically 15-50 days (average 28 days), during which the virus replicates in the liver but symptoms are not yet apparent.
Viremia: The virus is present in the bloodstream and detectable, often preceding symptoms.
Prodromal Phase: Initial non-specific symptoms like fatigue, nausea, vomiting, abdominal pain, fever, and dark urine. This phase usually lasts a few days to a week.
Icteric Phase: Characterized by the onset of jaundice (yellow skin/eyes), pale stools, and more pronounced symptoms. Liver enzyme levels, particularly Alanine Aminotransferase (ALT), are significantly elevated (e.g., ), indicating liver cell damage.
Detection of anti-HAV: Serological tests identify antibodies:
IgM anti-HAV: Detectable during the acute or recent infection phase and indicates current or very recent exposure.
IgG anti-HAV: Appears later and provides long-term immunity against future HAV infection. Its presence indicates past infection or vaccination.
Convalescence: Gradual resolution of symptoms and return of liver function to normal, usually within several weeks to months.
Hepatitis B
Hepatitis B can manifest as a self-limiting acute infection (most adults clear the virus) or a chronic infection, which can lead to lifelong complications such as cirrhosis, liver failure, and liver cancer. The outcome depends largely on the age of infection (infants are more prone to chronic infection).
The incubation period for HBV is typically 4-12 weeks, but can range from 6 weeks to 6 months. Following exposure, individuals may experience acute viremia or proceed to develop chronic infection if the virus is not cleared.
Important markers in HBV diagnosis and monitoring:
HBsAg (Hepatitis B surface antigen): Detectable during acute and chronic infection. Its presence indicates that the person is infectious.
Anti-HBs (Antibody to HBsAg): Indicates recovery from HBV infection and immunity, or successful vaccination.
HBeAg (Hepatitis B envelope antigen): Indicates active viral replication and high infectivity, correlating with higher viral loads.
Anti-HBe (Antibody to HBeAg): Suggests lower viral replication and reduced infectivity. In chronic infection, it may indicate seroconversion, but active disease can still occur.
Anti-HBc (Total core antibody): Appears during acute infection and persists indefinitely. It indicates past or current HBV infection but does not differentiate between acute and chronic. It consists of both IgM and IgG.
IgM anti-HBc: Indicates acute or recent HBV infection.
IgG anti-HBc: Indicates past or chronic HBV infection and persists for life.
HBV DNA: A quantitative measure of the actual number of viral particles in the blood, indicating viral load and activity, often used to monitor treatment response.
Hepatitis C
Hepatitis C is caused by an RNA virus known for its high genetic variability, with frequent mutations leading to diverse viral variants (genotypes and subtypes). This mutational capacity complicates vaccine development, contributes to treatment resistance, and necessitates genotyping for treatment selection.
Transmitted primarily via blood-to-blood contact (e.g., injection drug use, unsterile medical procedures, tattoo needles), sexual contact (less efficiently than HBV), and congenital routes (from mother to child during birth).
Major liver damage results from the chronic immune response against the persistently present virus. This leads to ongoing inflammation, fibrosis, cirrhosis, and a significant risk of hepatocellular carcinoma.
Diagnosis involves a two-step process:
Antibody levels (anti-HCV): A screening test to detect antibodies to HCV, indicating exposure to the virus. A positive result necessitates confirmatory testing.
Quantitative PCR (HCV RNA): Measures the actual viral load in the blood, confirming active infection and guiding treatment decisions. It can also be used for early diagnosis before antibodies develop.
Antiviral treatment, primarily Direct-Acting Antivirals (DAAs), is highly effective with high cure rates () but can be expensive. There is currently no vaccine available for Hepatitis C.
Rabies Virus Overview
Rabies is an enveloped RNA virus (Rhabdoviridae family, genus Lyssavirus) with a characteristic bullet shape. In the U.S., reservoirs include wild animals such as raccoons, skunks, bats, and foxes. Globally, domestic dogs are the primary reservoir, accounting for the vast majority of human rabies deaths.
The disease causes over 50,000 deaths annually worldwide, predominantly in developing countries where dog vaccination programs are insufficient. Rabies is almost always fatal once clinical symptoms appear.
Unfortunately, there is no effective antiviral treatment available once symptoms develop. Prevention through vaccination and prompt post-exposure prophylaxis is critical.
Pathogenesis of Rabies
The virus is typically inoculated into muscle tissue via a bite from an infected animal. It then replicates locally in muscle cells before entering the peripheral nervous system.
The virus spreads retrogradely (moves backward) along peripheral nerves to the central nervous system (CNS), including the spinal cord and brain. This neural transport is relatively slow.
Once in the CNS, the virus replicates rapidly, causing widespread neurological dysfunction. It then migrates centrifugally (outward) via nerves to other tissues, including salivary glands, which facilitates further transmission through bites.
Symptoms reflect CNS involvement and include non-specific signs (fever, headache, malaise) progressing to specific neurological symptoms like paralysis, salivation (hydrophobia and aerophobia due to painful spasms), and profound anxiety or agitation.
Symptoms and Stages of Rabies
Rabies progression can be divided into distinct stages:
Incubation Period: Highly variable, from a few days to over a year (average 2-3 months), depending on the bite location (closer to CNS = shorter incubation), severity of the wound, and viral load.
Prodrome (~1 week): Initial non-specific flu-like symptoms (fever, headache, fatigue, nausea, vomiting) and often a unique sensation (pain, paresthesia, itching, or tingling) at the site of the original bite, even if the wound has healed.
Acute Neurologic Stage (~1 week): This stage is characterized by specific neurological symptoms and can present in two main forms:
Furious Rabies (80% of cases): Characterized by hyperactivity, agitated behavior, hallucinations, fear of water (hydrophobia) due to painful spasms of the pharynx when attempting to drink, fear of fresh air (aerophobia), and generalized seizures. Excessive salivation is common.
Paralytic Rabies (20% of cases): Manifests with muscle weakness, flaccid paralysis developing gradually, often starting in the bitten limb and spreading. This form is less dramatic but equally fatal.
Coma and Death: Without aggressive medical intervention (e.g., intensive care support), the acute neurological phase progresses to coma, followed by respiratory failure and death, usually within weeks of symptom onset.
Prevention and Diagnosis of Rabies
Diagnosis of rabies in animals is primarily achieved post-mortem through direct fluorescent antibody (DFA) testing on brain tissue (necropsy). In humans, ante-mortem diagnosis is challenging but can involve testing saliva (RT-PCR), serum and CSF (antibodies), and skin biopsies from the nape of the neck (DFA).
Preventive measures are crucial due to the almost universally fatal outcome once symptoms appear:
Pre-exposure vaccination: Recommended for individuals at high risk (e.g., veterinarians, animal handlers, travelers to endemic areas).
Post-exposure prophylaxis (PEP): Administered immediately after potential exposure (animal bite). It consists of:
Wound care: Immediate thorough washing of the wound with soap and water.
Rabies Immune Globulin (RIG): Provides immediate passive immunity by neutralizing the virus around the wound site.
Rabies Vaccine: A series of injections that stimulate active immunity, given over several days.
Animal control: Vaccinating domestic animals, controlling stray animal populations, and avoiding contact with wildlife.
Hantavirus Overview
Hantaviruses are a group of enveloped RNA viruses (Bunyavirales order, Hantaviridae family) primarily associated with two severe human diseases: Hantavirus Pulmonary Syndrome (HPS) and Hemorrhagic Fever with Renal Syndrome (HFRS).
HPS is mainly caused by New World hantaviruses (e.g., Sin Nombre virus in North America), often transmitted by deer mice.
HFRS is caused by Old World hantaviruses (e.g., Hantaan virus, Puumala virus) found in Eurasia.
Transmission occurs through exposure to infected rodents or their excreta. Humans become infected by inhaling aerosolized virus particles from rodent urine, feces, or saliva (e.g., when sweeping contaminated areas).
Outbreaks have been noted in the U.S., such as the Yosemite National Park outbreak in 2012, highlighting the risk associated with rodent-infested environments.
Symptoms and Pathology of Hantavirus Syndromes
Hantaviruses, as enveloped RNA viruses, cause severe illness with distinct pathologies for HPS and HFRS:
Hantavirus Pulmonary Syndrome (HPS): Characterized by fever, myalgia, and severe pulmonary leakage. The virus infects endothelial cells lining blood vessels, leading to increased capillary permeability, particularly in the lungs. This results in rapid fluid accumulation in the lungs (pulmonary edema) and acute respiratory distress. Myocardial dysfunction can also occur.
Hemorrhagic Fever with Renal Syndrome (HFRS): Presents with fever, malaise, headache, abdominal pain, and often progresses to kidney failure and hemorrhagic manifestations (bleeding). It also involves increased vascular permeability, but predominantly affects the kidneys and other organs, leading to shock and disseminated intravascular coagulation (DIC).
HPS can have a high mortality rate (up to 35-50% in severe cases) within days of symptom onset due to rapid respiratory failure.
Epidemiology of Hantavirus
Hantavirus infections are zoonotic, meaning they are transmitted from animals to humans. They are not known to transmit from person to person.
Cases can be significantly reduced by minimizing contact with rodent habitats:
Rodent control: Sealing holes, trapping rodents, and keeping food in rodent-proof containers.
Safe cleanup: When cleaning areas potentially contaminated with rodent droppings or urine, use wet-cleaning methods and wear appropriate protective equipment (gloves, masks) to avoid aerosolizing viral particles.
Ventilation: Ventilate enclosed spaces for at least 30 minutes before cleaning.
There is currently no specific antiviral treatment or vaccine available for hantaviruses, making prevention through environmental control and exposure avoidance the primary strategy.